DK162529C - Antiviralt virksomme pyridinribonucleosider og farmaceutisk acceptable salte deraf - Google Patents

Antiviralt virksomme pyridinribonucleosider og farmaceutisk acceptable salte deraf

Info

Publication number
DK162529C
DK162529C DK114484A DK114484A DK162529C DK 162529 C DK162529 C DK 162529C DK 114484 A DK114484 A DK 114484A DK 114484 A DK114484 A DK 114484A DK 162529 C DK162529 C DK 162529C
Authority
DK
Denmark
Prior art keywords
ribonucleosides
acceptable salts
pharmaceutical acceptable
antivirally effective
pyridine
Prior art date
Application number
DK114484A
Other languages
Danish (da)
English (en)
Other versions
DK114484A (da
DK162529B (da
DK114484D0 (da
Inventor
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23881409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK162529(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK114484D0 publication Critical patent/DK114484D0/da
Publication of DK114484A publication Critical patent/DK114484A/da
Publication of DK162529B publication Critical patent/DK162529B/da
Application granted granted Critical
Publication of DK162529C publication Critical patent/DK162529C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
DK114484A 1983-03-10 1984-02-28 Antiviralt virksomme pyridinribonucleosider og farmaceutisk acceptable salte deraf DK162529C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/473,883 US4526988A (en) 1983-03-10 1983-03-10 Difluoro antivirals and intermediate therefor
US47388383 1983-03-10

Publications (4)

Publication Number Publication Date
DK114484D0 DK114484D0 (da) 1984-02-28
DK114484A DK114484A (da) 1984-09-11
DK162529B DK162529B (da) 1991-11-11
DK162529C true DK162529C (da) 1992-03-30

Family

ID=23881409

Family Applications (2)

Application Number Title Priority Date Filing Date
DK114484A DK162529C (da) 1983-03-10 1984-02-28 Antiviralt virksomme pyridinribonucleosider og farmaceutisk acceptable salte deraf
DK190590A DK170647B1 (da) 1983-03-10 1990-08-10 2,2-difluor-2-desoxyriboser, især til brug ved fremstilling af antiviralt virksomme nucleosider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK190590A DK170647B1 (da) 1983-03-10 1990-08-10 2,2-difluor-2-desoxyriboser, især til brug ved fremstilling af antiviralt virksomme nucleosider

Country Status (36)

Country Link
US (5) US4526988A (OSRAM)
EP (1) EP0122707B1 (OSRAM)
JP (2) JPS59175498A (OSRAM)
KR (1) KR860001283B1 (OSRAM)
AR (1) AR243533A1 (OSRAM)
AT (1) ATE29726T1 (OSRAM)
AU (1) AU565856B2 (OSRAM)
BG (1) BG40814A3 (OSRAM)
CA (2) CA1218647A (OSRAM)
CS (1) CS246075B2 (OSRAM)
CY (1) CY1489A (OSRAM)
DD (1) DD216468A5 (OSRAM)
DE (2) DE19675003I2 (OSRAM)
DK (2) DK162529C (OSRAM)
ES (1) ES8602840A1 (OSRAM)
FI (1) FI77870C (OSRAM)
GB (2) GB2136425B (OSRAM)
GR (1) GR81845B (OSRAM)
HK (1) HK44989A (OSRAM)
HU (1) HU193893B (OSRAM)
IE (1) IE57071B1 (OSRAM)
IL (2) IL80463A (OSRAM)
KE (1) KE3874A (OSRAM)
LU (1) LU88791I2 (OSRAM)
MX (1) MX9203246A (OSRAM)
MY (1) MY102025A (OSRAM)
NL (1) NL950018I2 (OSRAM)
NZ (1) NZ207358A (OSRAM)
PH (2) PH23240A (OSRAM)
PL (1) PL142437B1 (OSRAM)
PT (1) PT78181B (OSRAM)
RO (1) RO89963A (OSRAM)
SG (1) SG21889G (OSRAM)
SU (1) SU1442076A3 (OSRAM)
UA (1) UA5955A1 (OSRAM)
ZA (1) ZA841605B (OSRAM)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
RU1787160C (ru) * 1986-12-24 1993-01-07 Эли Лилли Энд Компани Способ получени иммуноглобулинового конъюгата
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
EP0277599A3 (en) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Fluorine containing cyclopentane derivatives and processes for their production
CA1340645C (en) * 1987-04-17 1999-07-13 Victor E. Marquez Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0630905B1 (en) 1987-08-28 1999-05-06 Eli Lilly And Company Process for selectively isolating beta-2'-deoxy-2',2'-difluorocytidine or its salts
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
DE68923387T2 (de) * 1988-02-16 1996-01-25 Lilly Co Eli 2',3'-Dideoxy-2',2'-difluornucleoside.
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
JP3090456B2 (ja) * 1988-03-16 2000-09-18 スクリップス クリニック アンド リサーチ ファウンデーション 治療剤として有用な置換アデニン誘導体
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
CA2012129A1 (en) * 1989-03-20 1990-09-20 Ramakrishnan Nagarajan Recovery of difluoro sugar
US4954623A (en) * 1989-03-20 1990-09-04 Eli Lilly And Company Recovery of difluoro sugar
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5256797A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5252756A (en) * 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
NZ247936A (en) * 1992-06-22 1995-05-26 Lilly Co Eli Stereoselective anion glycosylation process for the preparation of a beta anomer enriched nucleoside
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
BR9302427A (pt) * 1992-06-22 1994-01-11 Lilly Co Eli Processo estereo seletivo para a preparacao de um derivado de riboturanosila
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5256798A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401861A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5428176A (en) * 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5633367A (en) * 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
CA2171518A1 (en) * 1995-03-24 1996-09-25 Douglas Patton Kjell Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
JP2000501738A (ja) 1995-12-13 2000-02-15 イーライ・リリー・アンド・カンパニー α，α―ジフルオロ―β―ヒドロキシチオールエステル及びその合成
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5808020A (en) * 1996-08-12 1998-09-15 Associated Universities, Inc. Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
US6013790A (en) * 1996-09-25 2000-01-11 Board Of Regents University Of Nebraska-Lincoln Heavily fluorinated sugar analogs
CA2284263A1 (en) * 1997-03-24 1998-10-01 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
CA2322008C (en) 1998-02-25 2011-06-28 Emory University 2'-fluoronucleosides
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN101029022B (zh) * 2000-10-20 2011-01-12 卫材R&D管理有限公司 含氮芳环衍生物的制备方法
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002365256A1 (en) * 2001-10-25 2003-07-30 Eli Lilly And Company Gemcitabine in the treatment of smallpox
AU2003235676A1 (en) * 2002-01-15 2003-07-30 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
MXPA04007876A (es) * 2002-02-14 2005-06-20 Pharmasset Ltd Analogos de nucleosido fluorado modificados.
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
EP1631258A1 (en) * 2003-05-20 2006-03-08 Aronex Pharmaceuticals Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
PL1633766T3 (pl) * 2003-05-30 2019-09-30 Gilead Pharmasset Llc Modyfikowane fluorowane analogi nukleozydów
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
CN101337930B (zh) * 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
DK1711188T3 (da) 2004-02-06 2012-09-10 Threshold Pharmaceuticals Inc Anticancerterapier
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1773856B1 (en) * 2004-07-21 2012-02-01 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
US7858761B2 (en) * 2004-07-29 2010-12-28 Hanmi Pharm. Co., Ltd 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof
EP1812457A1 (en) * 2004-07-30 2007-08-01 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF ß-NUCLEOSIDES
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US20060173174A1 (en) * 2004-12-08 2006-08-03 Anne-Ruth Born Difluoronucleosides and process for preparation thereof
PT1831237E (pt) * 2004-12-17 2008-09-22 Lilly Co Eli Pró-fármaco amida da gemcitabina, suas composições e utilizações
BRPI0606480A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
EA011558B1 (ru) * 2005-03-04 2009-04-28 Дабур Фарма Лимитед ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ И СПОСОБ ПОЛУЧЕНИЯ ОБОГАЩЕННЫХ β-АНОМЕРОМ 2-ДЕЗОКСИ-2,2-ДИФТОР-D-РИБОФУРАНОЗИЛНУКЛЕОЗИДОВ
US7485716B2 (en) * 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
AU2006255706B2 (en) * 2005-06-03 2011-06-23 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
JP5177429B2 (ja) 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
AT502221A1 (de) * 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007015257A2 (en) * 2005-08-04 2007-02-08 Hetero Drugs Limited A process for the preparation of gemcitabine using novel intermediates
KR100990590B1 (ko) * 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 붕해성이 개선된 의약 조성물의 제조 방법
JP2009513623A (ja) 2005-10-28 2009-04-02 アーチ ファーマラブズ リミテッド 塩酸ジェムシタビンの改良された製造方法
CA2627598C (en) * 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
EP1960378A4 (en) * 2005-12-14 2011-05-25 Dong A Pharm Co Ltd PROCESS FOR PRODUCING 2 ', 2'-DIFLUORONUCLEOSIDE AND ITS INTERMEDIATE
EP1994042A4 (en) * 2006-02-06 2009-03-18 Reddys Lab Ltd Dr PREPARATION OF GEMCITABINE
KR20080099263A (ko) * 2006-02-07 2008-11-12 케마지스 리미티드 젬시타빈 및 관련된 중간체의 제조 방법
US20070249823A1 (en) * 2006-04-20 2007-10-25 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
JP5190361B2 (ja) * 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
KR100741310B1 (ko) * 2006-08-01 2007-08-01 (주) 유일팜테크 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
US8865737B2 (en) * 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (en) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
AU2008211952B2 (en) * 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5349342B2 (ja) * 2007-03-23 2013-11-20 ドンウ シンテック カンパニー リミテッド ２’−デオキシ−２’，２’−ジフルオロシチジンの製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101024667B (zh) * 2007-03-30 2011-01-26 湖北益泰药业有限公司 盐酸吉西他宾的合成方法
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
CN100475832C (zh) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
WO2009011924A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US20090069354A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
JP4253357B1 (ja) 2007-09-27 2009-04-08 株式会社湯山製作所 手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP2217247A4 (en) * 2007-11-06 2011-12-28 Pharmaessentia Corp NEW PROCESS FOR SYNTHESIS OF BETA NUCLEOSIDES
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
EP2252283B9 (en) * 2008-01-11 2019-03-20 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
US8071632B2 (en) * 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
AU2009237578C1 (en) 2008-04-18 2014-12-04 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR101630468B1 (ko) * 2008-06-12 2016-06-14 시노팜 타이완 리미티드 겜시타빈 염기의 결정성 다형체
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
ES2623016T3 (es) 2008-12-23 2017-07-10 Gilead Pharmasset Llc Fosforamidatos de nucleósido de 2-amino purina 6-O-sustituida
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JP5730854B2 (ja) * 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用
CA2757745C (en) * 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
US20120129799A1 (en) 2009-07-31 2012-05-24 Astron Research Limited stable composition of ready-to-use gemcitabine injection
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CN102947302A (zh) 2010-02-18 2013-02-27 西班牙国家癌症研究中心 三唑并[4，5-b]吡啶衍生物
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
MX350725B (es) 2010-03-31 2017-09-14 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN102153602B (zh) * 2011-02-24 2013-11-06 中国农业大学 呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
CN102153601A (zh) * 2011-02-26 2011-08-17 湖南欧亚生物有限公司 一种高选择性的制备盐酸吉西他滨以及其中间体的方法
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
RU2631240C2 (ru) 2011-04-01 2017-09-20 Дженентек, Инк. Комбинации соединений-ингибиторов акт и абиратерона, и способы применения
TWI462931B (zh) 2011-04-07 2014-12-01 Pharmaessentia Corp β－核苷的合成技術
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
JP2014511875A (ja) 2011-04-13 2014-05-19 メルク・シャープ・アンド・ドーム・コーポレーション ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102453064B (zh) * 2011-06-30 2014-07-09 江苏豪森药业股份有限公司 制备吉西他滨盐酸盐的方法
US9416154B2 (en) 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2013051994A1 (en) 2011-10-03 2013-04-11 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CN102417533A (zh) * 2011-10-28 2012-04-18 江苏正大清江制药有限公司 盐酸吉西他滨的合成方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NO2755614T3 (OSRAM) 2012-01-03 2018-03-31
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CA3152081A1 (en) 2012-04-04 2013-10-10 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
PL2869848T3 (pl) 2012-07-04 2017-04-28 F.Hoffmann-La Roche Ag Połączone kowalencyjnie koniugaty antygen-przeciwciało
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
MD20150036A2 (ro) 2012-10-08 2015-08-31 Idenix Pharmaceuticals, Inc. Analogi de 2'-cloro nucleozide pentru tratarea hepatitei virale C
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
EP2854864B1 (en) * 2013-07-10 2016-05-04 Asteriapharma GmbH Compositions comprising oligomers of gemcitabine for use in therapy
CN105792845A (zh) * 2013-07-26 2016-07-20 施瑞修德制药公司 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
KR102272773B1 (ko) 2013-10-29 2021-07-02 오츠카 세이야쿠 가부시키가이샤 2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로
US10080807B2 (en) 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C
EP3164419B1 (en) 2014-06-26 2024-07-24 F. Hoffmann-La Roche AG Anti-brdu antibodies and methods of use
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US20180044368A1 (en) * 2015-02-25 2018-02-15 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy
SI3386998T1 (sl) 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
US20180169120A1 (en) 2016-11-21 2018-06-21 Bexion Pharmaceuticals, Inc. Combination therapy including sapc-dops for the treatment of pancreatic cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
EP3581183B1 (en) 2017-02-08 2023-11-29 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
EP3618837A4 (en) 2017-04-26 2020-11-04 Thomas I. Kalman MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
MX2019013014A (es) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Tratamiento de carcinoma hepatocelular.
CA3071599A1 (en) 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
ES2986343T3 (es) 2017-09-18 2024-11-11 Univ California Anticuerpos contra CLAUDINA-6 y métodos para tratar el cáncer
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019139920A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
BR112020015745A2 (pt) 2018-02-02 2020-12-08 Maverix Oncology, Inc. Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
KR20210114971A (ko) 2019-01-11 2021-09-24 리포메딕스 파마슈티컬스 리미티드 미토마이신 c의 리포좀성 전구약물를 포함하는 리포좀 조성물 및 제조 방법
PT3941946T (pt) 2019-03-20 2025-03-26 Univ California Anticorpos anti-claudina-6 e conjugados de fármacos
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
WO2020222668A1 (en) 2019-04-30 2020-11-05 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
WO2025019361A1 (en) 2023-07-14 2025-01-23 Modulation Therapeutics, Inc. Scd1 inhibitors for treating hematolymphoid neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
FR1362039A (fr) * 1963-04-17 1964-05-29 Ct D Etudes Experimentales Et Nouveau procédé de préparation du semi-aldéhyde succinique
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents

Also Published As

Publication number Publication date
SG21889G (en) 1989-07-14
ATE29726T1 (de) 1987-10-15
FI77870C (fi) 1989-05-10
PL142437B1 (en) 1987-10-31
KE3874A (en) 1989-06-30
DD216468A5 (de) 1984-12-12
IE57071B1 (en) 1992-04-22
AU565856B2 (en) 1987-10-01
EP0122707A1 (en) 1984-10-24
RO89963A (ro) 1986-09-30
GR81845B (OSRAM) 1984-12-12
NL950018I2 (nl) 1997-03-03
FI840890A0 (fi) 1984-03-06
PH23240A (en) 1989-06-06
KR860001283B1 (ko) 1986-09-05
JPS59175498A (ja) 1984-10-04
KR840007883A (ko) 1984-12-11
MX9203246A (es) 1992-07-31
FI77870B (fi) 1989-01-31
CA1223869A (en) 1987-07-07
DE3466224D1 (en) 1987-10-22
UA5955A1 (uk) 1994-12-29
PH23593A (en) 1989-09-11
GB8405805D0 (en) 1984-04-11
IL71143A0 (en) 1984-06-29
DE19675003I2 (de) 2003-05-22
DK114484A (da) 1984-09-11
GB8610648D0 (en) 1986-06-04
JPH06102655B2 (ja) 1994-12-14
BG40814A3 (bg) 1987-02-16
PL246601A1 (en) 1985-08-13
IL80463A0 (en) 1987-01-30
EP0122707B1 (en) 1987-09-16
NL950018I1 (OSRAM) 1995-11-01
DK190590A (da) 1990-08-10
JPH069602A (ja) 1994-01-18
ZA841605B (en) 1985-10-30
DK162529B (da) 1991-11-11
GB2136425B (en) 1987-05-13
JPH0542438B2 (OSRAM) 1993-06-28
PT78181A (en) 1984-04-01
DK170647B1 (da) 1995-11-20
AU2537484A (en) 1984-09-13
NZ207358A (en) 1987-03-06
ES530364A0 (es) 1985-12-01
US5118820A (en) 1992-06-02
CA1218647A (en) 1987-03-03
CY1489A (en) 1989-12-08
US4692434A (en) 1987-09-08
GB2136425A (en) 1984-09-19
GB2172287B (en) 1987-05-20
AR243533A1 (es) 1993-08-31
IL71143A (en) 1988-07-31
DK114484D0 (da) 1984-02-28
US5015743A (en) 1991-05-14
ES8602840A1 (es) 1985-12-01
IL80463A (en) 1988-07-31
FI840890L (fi) 1984-09-11
US4526988A (en) 1985-07-02
PT78181B (en) 1986-08-05
CS246075B2 (en) 1986-10-16
IE840584L (en) 1984-09-10
HU193893B (en) 1987-12-28
SU1442076A3 (ru) 1988-11-30
DK190590D0 (da) 1990-08-10
HK44989A (en) 1989-06-09
MY102025A (en) 1992-02-29
LU88791I2 (fr) 1996-11-05
US4808614A (en) 1989-02-28
GB2172287A (en) 1986-09-17

Similar Documents

Publication Publication Date Title
DK162529C (da) Antiviralt virksomme pyridinribonucleosider og farmaceutisk acceptable salte deraf
DK59184A (da) Farmakologisk virksomme forbindelser og terapeutisk acceptable salte deraf
FI834351A0 (fi) Med hinder foersedd sulkonstruktion foer sportsko
FI844722L (fi) Med munstycke foersedd cigarrett.
DK592183D0 (da) Pyridinderivater
DK40984D0 (da) Benzoquinolinderivater
DE3381674D1 (de) Pyridin-derivate.
DK448684D0 (da) Alkyldiaminderivater og deres anvendelse som laegemidler
FI844725L (fi) Med munstycke foersedd cigarrett.
FI833010A0 (fi) Byggnadselement eller -skiva foersett med aongspaerr
FI833962A0 (fi) Med rotationsmaskineri foersedd tryckmediedriven slagborrmaskin
DK131884D0 (da) Farmaceutiske midler med antineoplastisk virkning
DK123083D0 (da) Pyridinderivater
DE3483563D1 (de) Pyridazinon-derivate und deren salze.
DK584683D0 (da) Pyridinderivater
DK406384D0 (da) Imidazobenzodiazepinderivater og disses anvendelse
DK164867C (da) Pyrimidooe4,5-gaaquinolin-derivater eller salte deraf og farmaceutiske formuleringer indeholdende disse
FI834814A0 (fi) Hopfaellbar kniv foersedd med bladlaos
DE3467167D1 (de) Pesticidal nitromethylene derivatives
DK311784D0 (da) 2-substituerede benzofuranderivater og salte deraf samt deres fremstilling og anvendelse
DK17683D0 (da) 2,5-benzodiazocinderivater og salte deraf
DK166372C (da) Phenethylaminderivater og pharmaceutisk acceptable salte deraf
FI830748A0 (fi) Lutningsanordning foer skopa i arbetsmaskin med snabblaosning
FI830227A0 (fi) Avvattningsanordning foer tak
FI833006A0 (fi) Halvmask foersedd med en filterbrygga

Legal Events

Date Code Title Description
PUP Patent expired